A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

Phase 1 Active not recruiting 256 enrolled AO GENERIUM

RandomizedParallel-groupSingle-blindOther

Summary

This is a randomized single-blind comparative parallel group study of the safety, pharmacokinetics of the solution form of Complarate and Actemra® in healthy volunteers. Participants received a single subcutaneous dose of tocilizumab 162 mg. The follow up period was 43 days.

Timeline

Start: 2024-06-20
Primary completion: 2025-04-30
Completion: 2025-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Complarate®	Unknown	162 mg	Subcutaneous

Indications

No indication recorded.